  
CONFIDENTIAL  
 [ADDRESS_91599] OF TRANSCRANIAL ALTERNATING CURRENT STIMULATION IN 
CHRONIC LOW BACK PAIN: A PI[INVESTIGATOR_72001]  
 
 
[STUDY_ID_REMOVED]  
  
September 17, 2017  
 
 
 
 
 
 
 
 
 
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91600] of  Transcranial  Alternating  
Current  Stimulation in  Chronic  Low 
Back Pain: A P ilot Study  
A PI[INVESTIGATOR_8571], RANDOMIZED, CROSSOVE R, DOUBLE -BLIND, SHAM -CONTROLLED, SINGLE -SITE STUDY OF THE 
EFFECT OF TRANSCRANI AL ALTERNATING CURRE NT STIMULATION IN SU BJECTS WITH CHRONIC LOW 
BACK PAIN  
Funding Mechanism:  National Institute of Mental Health (NIMH)  
Principal Investigator:  [CONTACT_19767] L McCulloch, PT, PhD, MS, NCS  
Co-Investigator:  Flavio Frohlich, PhD  
Protocol Number:  17-0870  
Version Number:  1.0 
Date:  March 29, 2017  
 
 
 
 
 
 
 
 
 
 
 
 
 
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 2 Initial version:  3/19/[ADDRESS_91601] OF ABBREVIATION S ................................ ................................ ................................ .........................  6 
STUDY SUMMARY  ................................ ................................ ................................ ................................ ... 9 
1 KEY ROLES  ................................ ................................ ................................ ................................ .......  10 
1.1 INDIVIDUALS ................................ ................................ ................................ ................................ .... 10 
1.2 INSTITUTIONS  ................................ ................................ ................................ ................................ .. 11 
1.3 OPTIONAL  ................................ ................................ ................................ ................................ .......  11 
1.4 FUNDING SOURCES  ................................ ................................ ................................ ...........................  11 
2 INTRODUCTION  ................................ ................................ ................................ ...............................  12 
2.1 BACKGROUND  ................................ ................................ ................................ ................................ . 12 
2.2 INVESTIGATIONAL AGENT  ................................ ................................ ................................ ...................  13 
2.3 DOSE RATIONALE  ................................ ................................ ................................ .............................  13 
2.4 STUDY AIMS/HYPOTHESES  ................................ ................................ ................................ .................  [ADDRESS_91602] SELECTION AN D WITHDRAWAL  ................................ ................................ ........................  15 
3.1 INCLUSION CRITERIA  ................................ ................................ ................................ .........................  15 
3.2 EXCLUSION CRITERIA  ................................ ................................ ................................ .........................  15 
3.3 STRATEGIES FOR RECRUITMENT AND RETENTION  ................................ ................................ ....................  16 
3.3.1  RECRUITMENT  ................................ ................................ ................................ ...............................  16 
3.3.2  RETENTION  ................................ ................................ ................................ ................................ ... 16 
4 BASIC STUDY DESIGN  ................................ ................................ ................................ ......................  18 
4.1 TREATMENT ASSIGNMENT PROCEDURES  ................................ ................................ ...............................  18 
4.1.1  RANDOMIZAT ION PROCEDURES  ................................ ................................ ................................ .........  18 
5 STUDY SCHEDULE  ................................ ................................ ................................ ............................  20 
5.1 SCREENING ................................ ................................ ................................ ................................ ...... 20 
5.1.1  SCREENING TELEPHONE CALL ................................ ................................ ................................ ............  20 
5.1.2  INITIAL SCREEN ING SESSION (VISIT 1) ................................ ................................ ................................ . 20 
5.2 STIMULATION SESSIONS ................................ ................................ ................................ .....................  21 
5.2.1  DAY 1 OF STIMULATION (VISIT 1 CONTINUED ) ................................ ................................ ......................  21 
5.2.2  DAYS 2 OF STIMULATION (VISIT 2) ................................ ................................ ................................ ..... 21 
5.3 FOLLOW -UP ................................ ................................ ................................ ................................ .... 21 
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 3 5.3.1  FOLLOW -UP EMAIL ................................ ................................ ................................ ........................  21 
5.3.2  UNBLINDING PROCEDURES  ................................ ................................ ................................ ...............  21 
6 STUDY PROCEDURES/EVA LUATIONS  ................................ ................................ ...............................  [ADDRESS_91603]  ................................ .. 27 
8 POTENTIAL RISKS AND BENEFITS ................................ ................................ ................................ ..... 28 
8.1 BENEFITS TO SUBJECTS AND SOCIETY  ................................ ................................ ................................ .... 28 
8.2 POTENTIAL RISKS................................ ................................ ................................ ..............................  28 
8.2.1  PSYCHOLOGICAL  ................................ ................................ ................................ ............................  28 
8.2.2  PHYSICAL  ................................ ................................ ................................ ................................ ..... 29 
8.3 REFERRALS FOR MEDICAL FOLLOW -UP OR PSYCHOLOGICAL COUNSELING  ................................ ....................  29 
8.3.1  PREGNANCY FOLLOW -UP................................ ................................ ................................ .................  29 
9 DATA AND SAFETY MONI TORING  ................................ ................................ ................................ ... 31 
9.1 FROHLICH LAB MONITORING PLAN ................................ ................................ ................................ ...... 31 
9.3 EARLY WITHDRAW AL OF PARTICIPANTS  ................................ ................................ ................................  32 
9.3.1  REASONS FOR WITHDRAWAL  ................................ ................................ ................................ ............  32 
9.3.2  DATA COLLECTION AND FOLLOW -UP FOR WITHDRAWN PARTICIPANTS  ................................ ......................  32 
9.4 TERMINATION OF STUDY  ................................ ................................ ................................ ....................  32 
10 SAFETY & REPORTING  ................................ ................................ ................................ ...................  33 
10.1  SAFETY PARAMETERS  ................................ ................................ ................................ ......................  33 
10.2  METHODS AND TIMING FOR ASSESSING , RECORDING , AND ANALYZING SAFETY PARAMETERS  .......................  33 
10.2.1  ADVERSE EVENTS  ................................ ................................ ................................ .........................  33 
10.2.1  SERIOUS ADVERSE EVENTS  ................................ ................................ ................................ .............  34 
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91604] KEEPI[INVESTIGATOR_1645]  ................................ ................................ ......................  38 
12.1  PHI  AND HIPAA ................................ ................................ ................................ ............................  38 
12.2  CONFIDENTIALITY  ................................ ................................ ................................ ...........................  38 
12.2.1  ACCESS TO SOURCE DOCUMENTS  ................................ ................................ ................................ .... 38 
12.2.2  SENSITIVE INFORMATION  ................................ ................................ ................................ ...............  38 
12.2.3  OTHER  ................................ ................................ ................................ ................................ .......  39 
12.3  SOURCE DOCUMENTS  ................................ ................................ ................................ ......................  39 
12.4  DATA MANAGEMENT RESPONSIBILITIES  ................................ ................................ ..............................  40 
12.5  DATA CAPTURE METHODS (REDC AP) ................................ ................................ ................................  [ADDRESS_91605] (IRB)  ................................ ................................ ................................  41 
13.3  INFORMED CONSENT PROCESS  ................................ ................................ ................................ ..........  41 
13.4  EXCLUSION OF WOMEN , MINORITIES , AND CHILDREN (SPECIAL POPULATIONS ) ................................ ..........  42 
13.5  PARTICIPANT CONFIDENTIALITY  ................................ ................................ ................................ .........  42 
13.6  STUDY DISCONTINUATION  ................................ ................................ ................................ ................  42 
14 PUBLICATION POLICY  ................................ ................................ ................................ ....................  43 
15 LITERATURE REFERENCE S ................................ ................................ ................................ ..............  44 
ZAEHLE, T., RACH, S. , & HERRMANN, C. S. (2010). TRANSCRANIAL  ALTERNATING CURRENT 
STIMULATION ENHANCES  INDIVIDUAL ALPHA ACT IVITY I N HUMAN EEG. PLOS ON E, 5(11), E13766. ... 47 
APPENDIX A: SCHEDULE  OF EVENTS  ................................ ................................ ................................ ..... 48 
APPENDIX B: AE REPOR T FORM  ................................ ................................ ................................ ............  49 
APPENDIX C: IRB AMEN DMENT T RACKING LOG  ................................ ................................ ...................  51 
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 5 APPENDIX D: AE REPOR T FORM  ................................ ................................ ................................ ............  52 
APPENDIX E: INFORMED  CONSENT QUIZ  ................................ ................................ ..............................  53 
APPENDIX F: NOTE TO FILE ................................ ................................ ................................ ...................  54 
APPENDIX G: TELEPHON E SCRIPT  ................................ ................................ ................................ ..........  55 
 
 
 
  
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91606]  
AE Adverse Event/Adverse Experience  
ANOVA  Analysis of Variance  
BIS/BAS  Behavioral Inhibition System / Behavioral Approach System  
CFR Code of Federal Regulations  
cLBP  Chronic low back pain  
CNS Central Nervous System  
Co-I Co-Investigator  
CRF Case Report Form  
DASS -[ADDRESS_91607]  
HRV  Heart Rate Variability  
Hz Hertz  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IDE Investigational Device Exemption  
IRI Interpersonal Reactivity Index  
JAMA  Journal of the American Medical Association  
LAR Legally Authorized Representative  
LBP Low back pain  
MCIS  minimally clinical important difference  
NAMI  National Alliance on Mental Illness  
NIH National Institutes of Health  
NIMH  National Institute of Mental Health  
NRB  Neurosciences Research Building  
ODI Oswestry Disability Index  
OHRE  Office of Human Research Ethics  
OHRP  Office for Human Research Protections  
PCS Pain catastrophizing Scale  
PFC  Pre-frontal cortex  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 7 PHI Protected Health Information  
PI [INVESTIGATOR_83984] -Efficacy Questionnaire  
rTMS  repetitive transcranial magnetic stimulation  
SAE Serious Adverse Event/Serious Adverse Experience  
SB Suicidal Behavior  
SI Suicidal Ideation  
SMC  Safety Monitoring Committee  
SOP Standard Operating Procedure  
SPI [INVESTIGATOR_83985] -CH University of North Carolina at Chapel Hill  
US [LOCATION_002]  
VAS Visual Analog Scale  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 8  
 
 
  
  
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91608] OF TRANSCRANIAL ALTERNATING CURRENT STIMULATION IN 
CHRONIC LOW BACK PAIN: A PI[INVESTIGATOR_83986]  17-[ADDRESS_91609] 6 months  
Study Center(s)  This is a single -site study performed at The University of North Carolina at 
Chapel Hill.  
Objectives (Purpose)  To test the feasibility of using tACS to treat patients with chronic pain, and to 
collect pi[INVESTIGATOR_83987] -scale studies. The treatment rationale is to renormalize the 
presumed pathological  structure of alpha oscillations in the prefrontal cortex 
(PFC) of patients with chronic pain.  
Number of Subjects  [ADDRESS_91610] a diagnosis of chronic pain as 
defined by a clinic ian, a >[ADDRESS_91611] low suicide risk.  
Description of 
Intervention 
(Procedures/methods)  20 participants will be randomized into one of two arms: to receive either [ADDRESS_91612] 
stimulation visit (then crossover the next visit) while in a relaxed, yet 
experimentally controlled state, by [CONTACT_84022] a nature movie such as 
“Reefscape” during stimulation.  
Related IRB 
Applications  n/a 
 
  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 10 1 KEY ROLES  
1.1 INDIVIDUALS  
Principal Investigator  [CONTACT_19767] L McCulloch, PT, PhD, MS, NCS  
Co-Investigator  Flavio Frohlich, PhD  
Medical Monitor  Karen L McCulloch, PT, PhD, MS, NCS  
Karen L McCulloch, PT, PhD, MS, NCS – Principal Investigator  
[CONTACT_11604] – Division of Physical Therapy  
Email: [EMAIL_1667]  
Office: 3024 Bondurant Hall  
Phone: (919)843 -8783  
 
Flavio Frohlich, PhD – Co-Investigator  
UNC – Chapel Hill Department of Psychiatry  
Email: [EMAIL_1219]  
Offic e: 4109F Neuroscience Research Building  
Phone: (919) 966 -4584  
 
Julianna Prim - Study Coordinator  
UNC - Department of Allied Health Science  
Email: [EMAIL_1668]  
Office: Medical School Wing C – Room 233  
Phone: (919) 962 -5271  
 
Morgan Alexander, BS/BA – Research Assistant  
UNC – Chapel Hill Department of Psychiatry  
Email: [EMAIL_1669]  
Office: Medical School Wing C – Room 233  
Phone: (919) 96 6-4755  
 
Charles Zhou, BS – Research Assistant  
Neuroscience Center  
Email: [EMAIL_1670]  
Office: Neuroscience Research Building  
Phone: (919) 966 -2682  
 
Juliann Mellin, BA – Research Assistant  
UNC – Chapel Hill  Department of Psychiatry  
Email: [EMAIL_1671]  
Office: Medical School Wing C – Room 233  
Phone: (919) 966 -9929  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 11 1.2 INSTITUTIONS  
The University of North Carolina at Chapel Hill  
1.3 OPTIONAL  
IRB 
The University of North Carolina – Chapel Hill  
Medical School Building [ADDRESS_91613]  
CB #7097  
Chapel Hill, NC [ZIP_CODE] -7097  
(919) [ADDRESS_91614]:  
Sponsor Name  [CONTACT_61616]/Grant 
Number  
National 
Institute of 
Mental Health 
(NIMH)  R01MH101547  Federal     
External Funding : This project is externally funded but UNC -CH is not the direct recipi[INVESTIGATOR_83988].  
UNC -CH Funding : This project is not funded through UNC -CH. 
Classified : This project is not classified.  
  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 12 2 INTRODUCTION  
This document is a protocol for a human research study. This study is to be conducted according to U.S. 
and international standards of Good Cli nical Practice (FDA Title 21 Part 312 and International 
Conference on Harmonization guidelines), applicable government regulations and Institutional research 
policies and procedures.  
2.1 BACKGROUND  
Chronic pain is a severe disabling problem within society,  affecting 25 -30% of the [LOCATION_002] 
population ( Baliki and Apkarian, 2015 ). The Institute of Medicine estimates that [ADDRESS_91615] annual costs totaling over half a trillion 
dollars (Institute of Medicine Committee on Advancing Pain Research, 2012).   Low back pain (LBP) is the 
second most prevalent  cause of disability in US adults and a common  reason for lost work days with an 
estimated [ADDRESS_91616] days of work per year ( Freburger et al., 2011).  The lifetime prevalence is as 
high as 79% in adults (Walker et al, 2004) and 84% in adolescents (Jeffries et al, 2007). The poor rates of 
recovery (58% at 1 month) and high rates of recurrence (73% in 12 months) contribute to high  social and 
economic costs (Pengel et al., 2003). Chronic low back pain (cLBP) does not have a defined source, and 
the mechanism of development is not fully understoo d (Luedtke et al. 2015). In chronic pain the 
relationship between nociception and pain is often weak or lost indicating abnormal integration and 
recent neurobiological investigations corroborate the crucial role of the brain by [CONTACT_84023] (Pi[INVESTIGATOR_83989]., 2016). It’s been hypothesized that in the absence  of a 
peripheral pathology, central sensitization contributes to the development and maintenance of non -
specific chronic low back pain (Luedtke et al. 2015). The hypothesized mechanisms are an increased 
release of excitatory neurotransmitters at spi[INVESTIGATOR_83990], influencing pain perception via the spi[INVESTIGATOR_83991] (Luedtke et al. 2015). Chronic pain is 
currently extensively studied, but therapeutic options to date are limited, and duration of the symptoms 
tends to make pain increasingly resistant to treatment.  Opi[INVESTIGATOR_83992]  (Ferrari et al. 2015)  limited evidence supporting its long -term effectiveness but a growing 
literature highlighting myriad risks of long -term us e, including: misuse, abuse/dependence, overdose, 
and death  (Chou et al., 2015 ). Deep brain stimulation has  shown promising results,  but less 
invasive  forms of stimulation also might be effective (Antal et al., 2010).  Some studies have shown 
that both a s ingle session and repeated sessions of  repetitive transcranial magnetic stimulation 
(rTMS)  and transcranial direct current stimulation (tCDS)  can relieve pain transiently in some  patients 
with chronic pain (Naro et al,, 2016, Antal et al., 2010),  but other s have found the effect to be  small and 
not significant (Jimenez -Torres et al, 2016; Luedtke et al. 2015). Heart rate variability (HRV) is commonly 
used to assess the autonomic nervous system function and has been shown to predict poor health 
outcomes (Goc kel et al, 2008).  Initially developed to evaluate the prognosis of cardiac diseases 
(Balanescu et al., 2004), heart rate variability (HRV) analysis has been utilized to assess autonomic 
functions in chronic pain conditions (Staud et al., 2008, Kang et al. , 2012).  When compared to healthy 
controls individuals with chronic pain had lower HF (high frequency band) powerin HRV representing 
less parasympathetic output in the altered cardiac autonomic regulation (Södervall et al., 2013). Gockel 
and colleagues (2 008) found a significant association between heart rate variability and perceived 
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 13 physical impairment in patients with chronic low back pain using Oswestry Disability Index scores. 
Patients with higher subjective disability had greater sympathetic dominanc e (lower high frequency 
band) than patients with minimal perceived disability.  
2.2 INVESTIGATIONAL AGEN T 
One alternative not yet explored is Transcranial Alternating Current Stimulation (tACS). tACS is a safe, 
non-invasive, easy -to-administer procedure t hat applies weak electrical currents to the scalp to 
modulate rhythmic brain activity patterns. In addition, the Frohlich Lab has used this technology in 
clinical trials to treat individuals with serious mental illness, such as depression and schizophrenia  
(Frohlich 2015, Frohlich et al., 2016). Previous research has demonstrated that tACS enhances alpha 
oscillations in healthy participants (Zaehle et al., 2010) and may thus help to renormalize the presumed 
pathological structure of alpha oscillations in th e pre -frontal cortex (PFC) of patients with chronic pain 
(Lustenberger et al., 2015).  
Therefore, tACS may be an important next step in treating chronic pain. As stated above, some patients 
are resistant to other therapi[INVESTIGATOR_83993]. 
Treatment with tACS may provide an alternative for patients with disabling chronic pain who have few 
options.  
2.[ADDRESS_91617] shown a relationship between alpha oscillations (8 -12 Hz) and attention ( Cooper 
et al., 2003), arousal, and emotion (Weinreich, Stephani, & Schubert, 2016; Gaeta et al., 2015). The 
substantial comorbidity of chronic pain and mental disorders and the close relationship between chronic 
pain and psychological factors indicates tha t brain dysfunction plays a central role in the development 
and maintenance of chronic pain ( Pi[INVESTIGATOR_83989]., 2016 ).Pain stems from dynamic  interactions between 
sensory and contextual (i.e., cognitive, emotional, and motivational) processes that are mediated by 
[CONTACT_84024] -forward and feedback processes in the human brain. Alpha/beta oscillations are linked to the 
feedback p rocess and a suppression of oscillations at alpha frequencies is associated with tonic pain. 
Previous studies in chronic pain have found an increase of theta oscillations, slowing of the peak alpha 
frequency, and increase in beta oscillations in the fronta l areas (Lim et al., 2016). These changes along 
with the alpha -gamma oscillation coupling having a strong pain predictive model (Pi[INVESTIGATOR_83989]., 2016) 
provide evidence alpha oscillations play an important role in chronic pain. Our proposed intervention of 
transcranial alternating current stimulation (tACS) at the alpha frequency (~10 Hz) has been shown to 
alter alpha oscillations with sustained effects (Kasten, Dowsett, & Herrmann, 2016). These data suggest 
that α -tACS at 10 Hz applied to the prefrontal cort ex could potentially alleviate many of the symptoms 
associated with chronic pain. While there is currently no literature in HRV response to tACS, a study in 
progress is investigating HRV during tACS in healthy individuals. Since tDCS has been shown to incr ease 
parasympathetic and decrease sympathetic activity (Montenegro et al., 2011) we hypothesize that tACS 
will also increase parasympathetic activation specifically the high frequency bands.  
2.4 STUDY AIMS/HYPOTHESE S 
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 14 2.4.1  PRIMARY OBJECTIVE  
NULL HYPOTHESIS . There is no  difference in parasympathetic tone in Heart Rate Variability, shown 
by [CONTACT_84025].  
ALTERNATIVE HYPOTHESIS . There is a  difference in parasympa thetic tone in Heart Rate Variability, 
shown by [CONTACT_84026].  
2.4.1  SECONDARY OBJECTIVE  
NULL HYPOTHESIS . There is no difference in self -reported perceived pa in rating between baseline 
and the active stimulation.  
ALTERNATIVE HYPOTHESIS . There is a difference in self -reported perceived pain rating between 
baseline and active stimulation.  
  
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91618] meet all o f the following criteria:  
 Provide signed and dated informed consent  
 Male or female, aged 18-65 
 Diagnosed with nonspecific chronic low back pain  by [CONTACT_30223], normal MRi if  they had imaging done  
 BMI is less than 30  
 Suffered from chronic pain for > 6 month s 
 Self-report pain measures (VAS) > 4 
 Meets criteria for low depression and suicide risk as defined by [CONTACT_51664] -D 
 1 month  free anticonvulsant medications, 48 hours of opi[INVESTIGATOR_73773] (can take over the 
counter pain killers)  
 Can be taking over the  counter pain killers  not day of session  (Refrain from taking over the counter 
medications such as antihistamines, albuterol, nasal decongestants for one week prior to stimulation 
sessions )  
 Capacity to understand all relevant risks and potential benefits of the study (informed consent)  
 Willing to comply with all study procedures and be available for the duration of the study  
 Women of reproductive potential must test negative on a pregnancy test prior to start of treatment  
 Speak and understand English  
3.2 EXCLUSION CRITERIA  
A potential participant who meets any of the following criteria will be excluded from participation in the 
study:  
 Radicular Pain  
 Diagnosis of eating disorder (current or within the past 6 months)  
 Diagnosis of OCD (lifetime)  
 ADHD (current ly under treatment)  
 Neurological disorders and conditions, including, but not limited to:  
o History of epi[INVESTIGATOR_002]  
o Seizures (except childhood febrile seizures and ECT -induced seizures)  
o Dementia  
o History of stroke  
o Parkinson’s disease  
o Multiple sclerosis  
o Cerebral a neurysm  
o Brain tumors  
 Medical or neurological illness or treatment for a medical disorder that could interfere with study 
participation (e.g., unstable cardiac disease, HIV/AIDS, malignancy, liver or renal impairment)  
 Prior brain surgery  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 16  Any brain devices/i mplants, including cochlear implants and aneurysm clips  
 Traumatic brain injury  
 (For females) Pregnancy or breast feeding  
 Anything that, in the opi[INVESTIGATOR_871], would place the participant at increased risk or preclude 
the participant’s full com pliance with or completion of the study  
Justifications for any exclusions based on race, gender, or ethnicity: Non -English speaking individuals 
are excluded because the ability to accurately and completely communicate study information, answer 
questions ab out the study, and obtain consent are necessary.  
Justification for excluding women or women who become pregnant:  Pregnant participants will be 
excluded despi[INVESTIGATOR_61571], since no safety 
data for  pregnancy is known to exist for tDCS/tACS studies. We will verify pregnancy status via a urine 
pregnancy test for all female participants prior to receiving treatment on Day 1 of Stimulation.  
3.3 STRATEGIES FOR RECRU ITMENT AND RETENTION  
3.3.1  RECRUITMENT  
This clinical trial will utilize multiple recruitment strategies in order to communicate this 
opportunity to as many potential participants as possible. Participants will be recruited from the 
following sources using IRB approved flyers and email scripts:  
 UNC University Physical Therapy clinic  locations  
 UNC Hospi[INVESTIGATOR_83994]  
 North Carolina Institutions of Higher Learning  
The UNC community will also be notified of the study through the informational notify.unc.edu system  and a 
research li sting will be created on http://allyresearch.org/  as well as on http://jointheconquest.org . A short 
description of the study will also be incl uded on the Frohlich lab websit e .We will also have a posting on the 
Frohlich lab website.  
 
The prevalence of chronic LBP in North Carolina has increased from 1992 to 2006 as it more 
than doubled in the 14 year interval from 3.9 to 10.2 percent (Freburger et al., 2009). Studies 
have also documented increases in visits to physicians, physical therapi[INVESTIGATOR_11437], and chiropractors 
(Martin  et al., 2008). UNC Healthcare has a chronic pain clinic as well multiple physical therapy 
locations allowing local access to a large chronic pain populatio n.  
3.3.[ADDRESS_91619] via email or 
phone.  
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91620] at 
forming a professional relationship with each participant so that they  feel comfortable and 
willing to discuss what may be sensitive information. Retention will be quantified by [CONTACT_84027] (the data from each session will be scored and 
documented the day of the session).  
  
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91621] with peak -to-peak amplitude of 2 mA. In both arms, 
participants will stay in a relaxed yet controll ed state by [CONTACT_84022] a nature movie (“Reefscape”) during 
stimulation.  
Eligible participants who complete this clinical trial will have a total of 2 visits; 2 days of stimulation (with 
1-3 weeks in between). Day one of stimulation will take approximately 2. 5 hours as eligibility will be 
confirmed at the beginning. Day 2 of stimulation will take approximately 2 hours. Two days after each 
stimulation day, participants will receive via email a follow -up survey to complete that will take 
approximately 15 minutes . We estimate that total participation will be approximately 6 hours over the 
course of 6 weeks. All time estimates take into consideration breaks and time variance in administration.  
4.1 TREATMENT ASSIGNMENT  PROCEDURES  
Participants will be randomized into  one of 2 arms ( see Figure 1 above ). This is a double -blind study, so 
neither the participant nor the research will know which treatment the participant is receiving, if any.  
4.1.1  RANDOMIZATION PROCED URES  
Charles Zhou will randomize 6 -digit stimulation codes which will be used by [CONTACT_84028]. These stimulation codes are directly linked to which treatment  participants receive 
(sham or 10 Hz tACS) and will be used with the XCSITE100 stimulator. An unblinded code sheet 
that matches these stimulation codes to treatment arm will be kept by [CONTACT_84029].  
The unblinded code sheet will have the following information:  
1. The initial identifier codes for all potential participants  
2. Stimulation code: 6 -digit numerical code for the stimulation session  
3. Condition number: Numerical code for the condit ion 
4. Condition name: [CONTACT_84050] 10 Hz tACS10 Hz tACS
10 Hz tACS10 Hz tACS Sham tACSSham tACS
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91622] stimulation code i s provided for each session.  
These linked codes ensure that the study coordinator and research assistants are kept blinded 
to which treatment each participant receives. Please see Data and Safety Monitoring  for more 
information on unblinding this informati on. 
  
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91623] in a private lab environment as well.  
5.1 SCREENING  
The screening process has been divided into two steps: phone screening and an initial session. The 
phone screening allows researchers to screen out participants based on self -report responses and for 
potential participants to become familiar with the study schedule, including procedures. The initial 
session allows researchers to confirm any preliminary diagnoses and assess for exclusion criteria that 
cannot be confirmed via phon e. 
5.1.[ADDRESS_91624] been answered, the participant will be asked if he/she is still interested in participating in 
the s tudy. If yes, the researcher will ask if the participant will provide verbal consent to begin 
the initial phone screening which will determine eligibility for the initial session.  A telephone 
script, which includes the screening questions, is provided in A ppendix G. If the participant meets 
initial criteria with these two assessments, the initial session will be scheduled and a reminder 
call or email will be given at least 24 hours before the initial session.  
5.1.2  INITIAL SCREENING SE SSION (VISIT 1)  
At day  1 of stimulation, participants will be guided through the consent form and the HIPAA 
authorization form and be given the time to ask any questions about the information discussed. 
To ensure that all aspects of the research are understood, participants may  be asked a series of 
questions about the research they are about to take part in ( Appendix E ). Once it is clear that 
the participant understands the consent form and HIPAA authorization, they may sign the 
forms.  
Following the consent process, the partici pant completes the ODI and DVPRS to measure 
disability and pain intensity on 0 -11 scale. The HAM -D and DASS -21 will access low suicide risk 
and depression level. The self -report measures: UCLA Activity Score, PCS, and PSEQ will access 
physical activity lim itations, pain experience, and confidence in daily activities.  Data on 
demographics, handedness,  stai, bis-bas, and opi[INVESTIGATOR_83995] -treatment will also be collected.  
Once eligibility has been confirmed and all relevant data collected, Day 1 of stimulation will 
begin.  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 21 5.2 STIMULATION SESSIONS  
5.2.1  DAY 1 OF STIMULATION  (VISIT 1 CONTINUED)  
Prior to starting any study procedures, female participants will be asked to take a urine 
pregnancy test to ensure continued eligibility. The 5xSST, FTF, and pressure pain threshold test 
will be administered before stimulation.  A resting state EEG will be recorded for 5 min before 
and after stimulation.  The participant will receive 40 minutes of sham or 10 Hz tACS stimulation 
(as per the initial randomization) while watchin g “Reefscape”. The stimulation will be followed 
by [CONTACT_84030], 5xSST, FTF, stimulation adverse effects questionnaire and 
perceived improvement ending the session.  
5.2.2  DAYS 2 OF STIMULATIO N (VISIT 2)  
Prior to starting any study procedures, female participants will be asked to take a urine 
pregnancy test to ensure continued eligibility. The ODI, DVPRS, 5xSST, FTF, and pressure pain 
threshold test will be administered before stimulation. A resting state EEG will be recorded for 5 
min before and after stimulation.  The participant will receive 40 minutes of sham or 10 Hz tACS 
stimulation (as per the initial randomization) while watching “Reefscape”. The stimulation will 
be followed by [CONTACT_84031], 5xSST, FTF, stimulation adverse effects 
questionnaire and perceived improvement ending the session.  
5.[ADDRESS_91625] the Frohlich Lab for unblinding information.  
 
  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 22 6 STUDY PROCEDURES/EVA LUATIONS  
6.[ADDRESS_91626] dem ographics, which include medical history and 
medication history. In addition, several other self -report measures will be used throughout this study. 
These measures are listed below and can be found in the attached documents.  
A. OSWESTRY DISABILITY INDEX (ODI)  is a 10 item self -report assessment to measure level of disability and 
monitor change over time. It takes only 5 minutes to complete with a MCID of 10 pts. (Fritz et al., 2001)  
B. DEFENSE AND VETERANS PAIN RATING SCALE (DVPRS)  is a modified numeric rating sc ale with faces and word 
descriptors. The MCID is [ADDRESS_91627] of chronic pain on 
other aspects of daily living (Buckenmaier et al., 2013).  
C. UCLA ACTIVITY SCORE is a self -report measure of 1 question to measur e activity level and change.  
D. PAIN CATASTROPHIZING SCALE (PCS)   is a 13 item self -report measure designed to quantify an individual's pain 
experience.(Sullivan et al., 1995)  
E. PAIN SELF-EFFICACY QUESTIONNAIRE (PSEQ)  is a 10 -item questionnaire measuring confi dence in ability to 
perform specific tasks or copi[INVESTIGATOR_54241] (Nicholas, 2007)  
F. DEPRESSION ANXIETY STRESS SCALE (DASS -21) is a 21 item short form self -report questionnaire (Original DASS is 
42 items) that provides a quantitative measure of depression, anxi ety, and stress experienced in the past 
week. It is important to note that the DASS -21 is not a diagnostic tool (Lovibond & Lovibond, 1995) . 
6.2 CLINICAL MEASURES  
In addition to self -report measures, several clinical measures will be used throughout this s tudy, both 
for measuring change over time and for diagnostic use. These measures are listed below and can be 
found in the attached documents.  
A. HAMILTON PSYCHIATRIC RATING SCALE FOR DEPRESSION (HAM -D) is a 21 -item assessment to rate the severity of 
depressio n in patients (Hamilton, 1960). This measure is being used to assess levels of depressive 
symptoms and to determine suicide risk. Low suicide risk for this study is defined as scoring [ADDRESS_91628] (5XSST)  is a quick and easy to administer test of an individual’s ability to 
transition between sitting and standing five times in a row and has been previously tested in chronic LBP 
populations. We will use as a measure of functional lower limb  muscle strength and in quantifying 
functional change of transitional movements with MCIS between 4 -9 seconds (Simmonds et al., 1998, 
Andersson et al., 2010) .  
C. FINGERTIP -TO-FLOOR TEST (FTF)  is a valid, reliable, and responsive test in individuals with chro nic low back 
pain. It measures trunk flexion and the MCIC varies (approx. 10 cm) (Perret et al., 2001)  
6.3 SPECIAL ASSAYS OR PR OCEDURES  
6.3.1  SPECIAL PROCEDURES  
Each participant will attend two days of stimulation for this study. Each participant will be 
randomly assigned to one of two treatment arms (sham or 10 Hz tACS) then the opposite on the 
second visit. For more information on the stimulation procedures, see  section 7.[ADDRESS_91629] .  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 23 6.3.2  EKG PROCEDURES  
To obtain a measure of the heart rate during both stimulation conditions, ECG electrodes as part 
of the EEG acquisition system are placed on the participant's body. Ideally one electrode will be 
placed below the left collarbone and a second below the right chest.  The EKG will be recorded 
for the full [ADDRESS_91630] any chan ge(s) at the neurophysiological level, a resting state EEG 
will be recorded before and after stimulation during both sessions. This measurement will 
contribute to the design of novel network -level biomarkers of chronic pain and of response to 
pain.  
 
6.[ADDRESS_91631] udies (IRB #14 -1622, #14 -3285, and #14 -
0600) will be administered at the end of each stimulation session. This questionnaire will be used as a 
safety measure and to collect data on participant experience. Please see 10.[ADDRESS_91632] will be performed for any female participant who is unable to confirm 
pregnancy status.  
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91633] an influence on 
effectiveness of brain stimulation. Within the central nervous system, BDNF regulates survival, 
proliferation, and synaptic growth as well as directly influences synaptic plasticity in the adult 
human brain (Antal et al., 2010a). Egan et al. (2003) demonst rated that Val66Met, a single 
nucleotide in the BDNF gene, has function consequences in healthy humans, including 
decreased epi[INVESTIGATOR_83996] a reduction in recall capacity. This 
polymorphism is common in over one third of the Caucas ian population (65% Val66Val to 35% 
Val66MET) (Pezawas et al, 2004; Hariri and Weinberger, 2003). Kleim et al. (2006) found that 
individuals with the Val/Val polymorphism respond to tDCS and transcranial magnetic 
stimulation (TMS) treatments with expected change, whereas, individuals expressing Val/MET 
allele do not. These authors indicate the difference to be caused by [CONTACT_84032]/MET allele. These findings suggest that individual efficacy of 
treatments using bra in stimulation may be partially genetically predetermined and should be 
taken into account when preforming such procedures. Accordingly, we will conduct genotypi[INVESTIGATOR_83997].  We will perform explorato ry 
analyses in which we group participants by [CONTACT_84033].  A saliva sample will also test for levels 
of progesterone, estradiol,  
INSTRUCTIONS FOR SPEC IMEN PREPARATION , HANDLING , AND STORAGE . The saliva sample will be collected 
using 2mL DNA collection kit from DNA Genotek. Before sample collection, it is imperative that 
the participant does not eat, drink, smoke or chew gum for at least 30 minutes before providing 
a sample.  Once the participant provides the 2mL sample, the collection tube is closed and a 
liquid from the lid will be released into the tube. The original lid will be removed and replaced 
with a small cap and the tube will be agitated for 5 seconds.  The sample is then returned to the 
plastic packaging and labeled with the date of collection, th e study name, and the participant ID.  
These samples are kept in a secure location until the completion of data collection.  
  
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91634] reported due to the use of transcranial brain 
stimulation. Previous studies in the Frohlich lab that used comparable devices (i.e., the commercial, CE -
certified Neuroconn Plus stimulator) have always been classified as “non -significant ri sk” by [CONTACT_84034]. The Neuroconn Plus stimulator and the XCSITE100 stimulator are electrically equivalent and provide 
the same stimulation.  
The XSCITE100 is the first non -invasive brain stimulator designed for research purposes to provide an 
active sham for tACS and record the stimulation output for later validation. This stimulator may apply 
either tDCS or tACS for up to 40 minutes (2400 seconds) with appropriate current ramp -up at the 
beginning of stimulation and ramp -down at the end of stimulation . Both tDCS and tACS may be applied 
for currents between 100 μA and 2 mA (peak -to-peak for tACS).  
The stimulator has two main components:  
1. Android tablet with user interface application (i.e., App)  
2. Stimulator with:  
a. Microprocessor  
b. Function generator chip  
c. Voltage controlled current source  
d. Safety circuitry  
To ensure appropriate blinding for each stimulation session, there are designated unblinded individuals 
to ensure the appropriate stimulation parameters are applied to each participant. These individuals will  
not interact with participants and will only be involved with the creation of a study file and validation of 
stimulation waveform.  
7.1 SAFETY FEATURES  
Current Sensor Circuit . A 33.2 Ω sense resistor is placed in series with the stimulation electrodes on t he 
high side. Since high -side current sensing is used, any short circuit of the electrode terminals to ground 
will be detected. The stimulation current flows through this resistor and creates a voltage. The voltage 
across this resistor is sensed and amplif ied by [CONTACT_84035]628 difference amplifier. The gain of the difference 
amplifier is set to 9.9039. The current sensor voltage is then shifted before it is read by [CONTACT_84036].  
Voltage Sensor Circuit. The differenti al voltage across the electrodes is measured so that the impedance 
can be calculated. The voltage is measured by [CONTACT_84037] a unity gain op -amp circuit. The voltage output is then shifted before it is read by [CONTACT_84038].  
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91635] the participant 
from high currents. The stages are as follo ws: 
1. AUTOMATIC SOFTWARE CU RRENT CUTOFF . The output of the current sensor described above is read by a 
microprocessor, which compares the reading to a value of ±[ADDRESS_91636]. Since high -side current sensing is used (described above), any short circuit of the electrode 
terminals to ground will be detected.  
2. AUTOMATIC HARDWARE CU RRENT CUTOFF . The output of the current sensor is fed into a pair of comparators 
which detect if the current exceeds ±4.[ADDRESS_91637] -acting fuse is in series with the electrode connector. If 
the above two over -current detection methods fail, the fuse will below, and the stimulator will no longer 
be electronically connected to the device.  
4. POWER SUPPLY FUSE . Finally, if for no ot her reason the entire device draws too much current, the main 
power supply fuse is blown. This fuse is sized with a cutoff of 200% of steady -state operating current.  
7.[ADDRESS_91638]  
Yellow: Relay control line  
Green : Current through 
electrode (goes from 
negative current to zero)  
Blue : Current sensor 
output (has lowpass 
filter)  
Purple : SR latch output  
 
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 27 After participants ha ve completed the daily questionnaire, they will be comfortably seated. The researcher(s) will 
first measure their head using the 10 -20 system for accurate electrode placement. Participants will then be fitted 
with the 3 electrodes for stimulation. Electrod es will be applied using Ten20 conductive paste, 5x5cm electrodes 
placed over F3 and F4 with a 5x7cm placed over CZ as a return electrode. The participant will be in a relaxed yet 
experimentally controlled state by [CONTACT_84022] “Reefscape”. One session of stim ulation will be performed per day for 
40 minutes. For the 10 Hz tACS stimulation, there will be a 10 second ramp -in and ramp -out with 40 minutes of 
stimulation for a total of 2420 seconds. Stimulation waveforms are sine -waves with a peak -to-peak amplitude of 2 
mA. The sham stimulation will include 10 seconds of ramp -in to 1 minute of 10 Hz tACS with a ramp -out of 10 
seconds for a total of 80 seconds of stimulation. As a covariate, heart rate will be recorded throughout stimulation.  
Stimulation devices will  be programmed and codes will be randomized to one of the two experimental arms. 
Researchers will enter the participant -specific code into the App that controls the stimulation and monitor 
participants during the 40 minutes of stimulation.  
The study coordi nator and/or the research assistant will be thoroughly trained and have trainings documented on 
the transcranial stimulation device and will be present during all stimulation sessions. To monitor side effects of 
stimulation, a daily questionnaire will be a dministered after each stimulation session.  
7.[ADDRESS_91639]. Follow -up emails will be sent out 2 days after 
scheduled visit.  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 28 8 POTENTIAL RISKS AND BENEFITS  
8.1 BENEFITS TO SUBJECTS  AND SOCIETY  
Chronic pain is a debilitating disorder that involves problem in the feedback (top -down) mechan ism in 
pain processing. Our novel approach introduces non -invasive brain stimulation for brain dysfunction and 
has the potential to treat symptoms not only in chronic pain, but also in depression and schizophrenia 
(Frohlich, 2015; Frohlich et al., 2016). A dditionally, tACS has the potential to provide a treatment option 
that is safe, scientifically -supported, low -cost, easy -to-administer method to effectively reduce 
symptoms in patients suffering from chronic pain. The chance to understand and develop a new  
treatment for chronic pain is an important step in helpi[INVESTIGATOR_83998], from physical handicaps to common psychiatric comorbidities including opi[INVESTIGATOR_83999]. If tACS is feasible and eff ective for patients with chronic pain, findings will 
provide persuasive preliminary results for the National Institutes of Health (NIH) and National Institute 
of Mental Health (NIMH) proposals to fund a large -scale clinical trial for patients with this ser ious 
disorder.  
This study has not been designed to benefit the individual participants. However, participants in this 
study may experience some degree of relief from chronic pain symptoms as a result of tACS treatment. 
There are no serious risks to the pa rticipant from the treatment used in this study.  
8.2 POTENTIAL RISKS  
8.2.1  PSYCHOLOGICAL  
Risk of Embarrassment : Self -report and clinical assessments contain questions regarding 
sensitive personal information. This risk is necessary in order to assess symp tomology. 
Participants will be assured upon intake that only study personnel will see any clinical ratings.  
Risk of Confidentiality . All subjects will be informed during the consent process that if they 
report violent or suicidal ideation/behavior, this information will be kept confidential unless the 
subject reports a plan to hurt themselves or an identified victim. In this case, appr opriate 
referrals will be made and the subject will be advised to end their participation in the study.  
In the unlikely event of a breach of confidentiality, people might discover that an individual was 
involved in this research study. Some people might no t agree with the principle of participating 
in research or of changing natural brain activity. To avoid breaches in confidentiality, study 
documents that contain personal information, including the informed consent, and the 
document that links study ID num bers to personal identifying information are kept in locked 
filing cabinets in locked rooms, separate from any source documents containing participating 
dummy identifiers. All data is stored in locked cabinets inside locked offices; electronic data will 
be stored only on password -protected computers, and data encryption methods will be used 
during communication between investigators. Only study personnel will have access to these 
data. All study staff participate in annual human participating training that includes education 
about responsibilities to minimize the risk of confidentiality breach.  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 29 8.2.2  PHYSICAL  
Risk of Injury and Discomfort : Transcranial current stimulation has been used without any 
reports of serious side -effects for more than a decade. This stimulation made has NOTHING to 
do with electroconvulsive therapy that applies many orders of magnitude higher stimulation 
current. Rather, transcranial current stimulation is so weak that it does not cause super -
threshold activation of neurons (Frohlich a nd McCormick, 2010). In particular, tACS has been 
used without reports of any serious side -effects. Some participants report a transient mild 
tingling, burning, or itching underneath the electrodes and headache, but no other side effects 
have been noted. I mportantly, it remains unclear if these mild side -effects were caused by [CONTACT_61599]. In order to monitor these side -effects, we will be administering 
an adverse effects stimulation questionnaire after each stimulation session to det ermine 
whether these effects were experienced. Research personnel present during these sessions will 
also check in with the participant periodically during the stimulation to see whether they are 
comfortable. If any side -effect occurs (rated by [CONTACT_84039] “moderate”) or 
the participant is experiencing severe discomfort, the stimulation will be immediately stopped.  
8.3 REFERRALS FOR MEDICA L FOLLOW -UP OR PSYCHOLOGICAL COUNSELING  
There is a purely theoretical likelihood that stimulation o f neuronal circuits can lead to epi[INVESTIGATOR_84000]. To minimize this occurrence, we screen and exclude patients with personal and family history 
of neurological conditions from the study. If abnormalities or a seizure is witnessed during the course of 
the study, a referral will be made to the UNC Department of Neurology for follow -up. In the theoretical 
event that a seizure is witnessed that involves the loss of consciousness, the patient will be told not to 
operate a motor vehicle until cleared by [CONTACT_61601] . 
We will be using the Hamilton Psychiatric Rating Scale for Depression (HAM -D) to assess depression and 
suicide risk at the initial session. Inclusion criteria states that the patient must be low suicide risk, 
potential participants that have an above “lo w risk” designation that is currently clinically relevant will 
not be eligible for the study . 
To ensure participant comfort, a study coordinator or research assistant will periodically check in with 
the participant about any side -effects he/she may be exp eriencing during each stimulation session. 
Following the conclusion of the stimulation session, the participant will receive an Adverse Effects 
Questionnaire to report on any of the side -effects he/she may have experienced. This questionnaire 
reports side -effects on a likert scale (1=Absent, 2=Mild, 3=Moderate, 4=Severe). If the participant 
reports side -effects of Moderate to Severe intensity, a study coordinator or research assistant will 
discuss the side -effects experienced and note this response. The med ical monitor will be contact[CONTACT_84040]’s verbal 
confirmation of intensity.  
8.3.[ADDRESS_91640] on Day 1 of Stimulatio n. If, after testing 
negative at Day 1 of Stimulation (meeting inclusion criteria), a participant reports becoming 
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 30 pregnant during the course of the study, she will be withdrawn from further participation. There 
are no plans to follow participants who beco me pregnant while enrolled in the study.  
  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 31 9 DATA AND SAFETY MONI TORING  
9.1 FROHLICH LAB MONITOR ING PLAN  
The purpose of this monitoring plan is to present the Frohlich Lab’s approach to monitoring clinical 
trials. The plan facilitates compliance with good clinical practice (GCP):  
a. The rights and well -being of human subjects are protected.  
b. The reported trial data are accurate, complete, and verifiable from source documents  
c. The conduct of the trial is in compliance with the currently approved protocol/amendmen t(s) with GCP, 
and with applicable regulatory requirement(s)  
This section identifies key monitoring activities and specifies the data to be reviewed over the course of 
a clinical trial. This is a single site, investigator -initiated, clinical trial, so ther e will be no site monitoring 
plan in place.  
The latest version of the approved IRB application for this clinical trial will be followed at all times. This 
responsibility falls into the hands of the study coordinator and research assistants. If at any time there is 
a deviation from protocol, the deviation from protocol log will be filled out. All team members will be 
trained on how and when to use this log. The most up -to-date IRB application will be on file in the 
Clinical Trials office in Room 233 of the M edical School Wing C. Deviations will be sent to the IRB every 
4-6 weeks (if necessary).  
Periodically, study staff should review 3 randomly selected inform consent forms to ensure that (1) 
these forms have been filled out appropriately, and (2) the consent  form process was followed and 
properly documented. Should any consent form be in violation, the research team will perform and 
document a complete review of all consent forms.  
AE and SAE are clearly defined in this document. Documents of AE and SAE can b e found in the study 
binder on file in the Clinical Trials office in Room 233 of the Medical School Wing C. It is the 
responsibility of the study coordinator to report all events to the PI [INVESTIGATOR_2993] a timely manner (see 9.3 
Reporting Procedures ). All AEs and SAEs  will be discussed with the PI. For our practices, we have adapted 
the decision tree provided by [CONTACT_84041] -CH IRB to assist with reporting of such events.  
Periodically, the study coordinator should also choose one CRF/eCRF and Source Document to assess for 
completion and maintenance. In addition, the PI [INVESTIGATOR_84001]. The PI [INVESTIGATOR_84002] -only access. This allows the PI [INVESTIGATOR_84003], but does not allow t he PI [INVESTIGATOR_84004], change, or input any data.  
A data safety monitor will review blinded AEs every month. The DSMB will assess recruitment and will 
only evaluate safety if an unanticipated concern arises.  
 
 
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 32 9.3 EARLY WITHDRAWAL OF PARTICIPANTS  
9.3.1  REASONS FOR WITHDRAWAL  
A study participant will be discontinued from further participation if:  
 The participant meets any exclusion criteria (either newly developed or not previously 
recognized).  
 Anything that, in the opi[INVESTIGATOR_871], would place the partic ipant at increased risk or 
preclude the participant’s full compliance with or completion of the study.  
Participants are free to withdraw from participation in the study at any time upon request.  
9.3.[ADDRESS_91641] had no seizures occur (Berlim et al., 2013).  
The study will also be stopped (at least temporarily) if studies provide evidence that transcranial cur rent 
stimulation caused brain damage or other harmful effects on subjects, either short -term or long -term. 
Examples of findings that might trigger a safety review are the number of SAEs overall, the number of 
occurrences of a particular type of SAE, severe  AEs/reactions, or increased frequency of events.  
The reasons for stoppi[INVESTIGATOR_84005]:  
 Increased pain due to treatment (>25% of participants asked to seek additional health care)  
 If a seizure occurs during a stud y visit, a temporary hold will be placed on the clinical trial  
The IRB will also be informed promptly and provided the reason(s) for the termination of suspension 
of by [CONTACT_093], as specified by [CONTACT_8146](s).   
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 33 10 SAFETY & REPORTING  
It is important to assess safety over the course of this study. This section describes in detail how safety is 
assessed, reporting of Adverse Events, Serious Adverse Events, and Unanticipated Problems. This section 
is a reference for internal u se. 
10.1  SAFETY PARAMETERS  
SUICIDE RISK. Participants with high suicide risk (SI or SB) will be excluded from our study.  
STIMULATION SIDE EFFECTS . A stimulation adverse effects questionnaire used in previous studies will be 
administered at the end of each stimulation session and at the [ADDRESS_91642] data on participant expe rience. The adverse effects 
questionnaire asks participants to respond on a 4 point likert scale on the severity of symptoms 
experienced during the stimulation session (1 = abstent, 2 = mild, 3 = moderate, 4 = severe). The side 
effects listed are headache,  neck pain, scalp pain, tingling, itching, ringing/buzzing noise, burning 
sensation, local redness, sleepi[INVESTIGATOR_008], trouble concentrating, improved mood, worsening of mood, 
dizziness, flickering lights, and other (specify). Participants are also asked to rate on a 5 point likert scale 
how related they believe the side effects to be to stimulation (1 = no relation, 2 = remote, 3 = possible, 4 
= probable, 5 = definite).  
In addition to this survey, the study coordinator or research assistant will periodically chec k in with the 
participant during the stimulation session to assess side effects.  
10.[ADDRESS_91643] ING, AND ANALYZING S AFETY 
PARAMETERS  
10.2.1  ADVERSE EVENTS  
All AEs, including local and systemic reactions not meeting the criter ia for “serious adverse 
events”, will be captured on the appropriate CRF. In addition, the AE Report Form will be 
completed by [CONTACT_9137] (Appendix B). The AE Report Form includes the following:  
 What is known about the therapy  
 What is known abou t previous reported side effects  
 If the AE occurred in temporal relation to the therapy  
 Whether or not the AE improves or disappears when treatment is stopped  
 Whether the AE is worsening of baseline symptoms  
 Whether the AE is related to concurrent medical condition or medication use  
Once complete, this form will be given to the PI [INVESTIGATOR_7706] -I, who will review, comment, and sign 
this form. Completed forms will be placed in the participant’s folder.  
In addition, the study coordinator will document any AE occurre nce on the AE log ( Appendix D ), 
which includes information such as the date of the AE, severity, relationship to the treatment 
(assessed by [CONTACT_978] [INVESTIGATOR_7706] -I*), actions taken, and outcome(s). The log will be reviewed and 
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 34 initialed by [CONTACT_978] 72 hours after be ing completed. All AEs occurring during the clinical trial will 
be documented appropriately regardless of relationship to tACS. All AEs will be followed to 
adequate resolution and will be graded for severity and relationship to study treatment. Any 
medical  condition noted at the initial session will be considered at baseline and not reported as 
an AE.  
All AEs will be graded for severity using the following guidelines:  
 ASYMPTOMATIC . The participant is exhibiting no symptoms due to this event; no treatment 
needed.  
 MILD. Event results in mild or transient discomfort, not requiring intervention or treatment; does 
not limit or interfere with daily activities (e.g., insomnia, mild headache)  
 MODERATE . Event is sufficiently discomforting so as to limit or interfere with daily activities; may 
require interventional treatment (e.g., fever requiring antipyretic medication). In the case of a 
moderate AE, the medical advisor may recommend an over the counter medication.  
 SEVERE AND UNDESIRABLE . Event results in significant  symptoms that prevent normal daily activities; 
may require hospi[INVESTIGATOR_84006] (e.g., anemia resulting in blood transfusion).  
Changes in the severity of an AE will be documented with the Note to File document (Appendix 
E) and will be filed in the participant’s folder.  
*Relationship to Study Products : The PI [INVESTIGATOR_7706] -I will together determine whether an AE is 
associated with the study treatment. The event will be labeled associated if the event is 
temporally related to the administration of a therapy and no other factors can explain the event. 
The event will be labeled as not associated if the event is temporally independent of the study 
treatment and can be explained by [CONTACT_84042], such as major life events.  
10.2.1  SERIOUS ADVERSE E VENTS  
Serious Adverse Event (SAE): An SAE, as defined by [CONTACT_18121], consists of adverse events that 
result in death, require either inpatient hospi[INVESTIGATOR_84007], 
are life -threatening, result in a persistent or significant disability/incapacity or result in 
congenital anomaly/birth defect.  Other important medical events, based upon appropriate 
medical judgment, may also be considered Serious Adverse Events if a trial participant’s health is 
at risk and intervention is requi red to prevent an outcome mentioned.  
All SAEs will be recorded on the Serious Adverse Events Form (Appendix B), documented in the 
UE/SAE log and reported to the IRB.  The SAE Form will be completed by [CONTACT_9137], 
and includes information relating to the onset and nature of the SAE, relationship to the study 
treatment, seriousness of the SAE, treatment required as a response to the SAE, and outcome.  
This form will be filed in the participant’s folder at the resolution of the event.  The st udy 
coordinator will complete the UE/SAE log (Appendix D) which includes information such as the 
date of the event, time at which the study team was informed of the event, details, when the 
IRB was notified, and the date that the SAE form was completed.  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 35 10.2.2  UNANTICIPATED PROBLE MS 
Unexpected Events (UE) will be recorded on the UE/SAE log (Appendix D) and will include 
information such as the date of the event, when the study team was informed of this event, 
details of the event, when the IRB was notified, and whether the SAE form was completed.  The 
IRB will be notified of each UE that may occur during the study.  
The Office for Human Research Protections (OHRP) considers unanticipated problems involving 
risks to subjects or others to include, in general, an y incident, experience, or outcome that 
meets all of the following criteria:  
 unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that 
are described in the protocol -related documents, such as the IRB -approved research p rotocol 
and informed consent document; and (b) the characteristics of the subject population being 
studied;  
 related or possibly related to participation in the research (in the guidance document, possibly 
related means there is a reasonable possibility tha t the incident, experience, or outcome may 
have been caused by [CONTACT_3459]); and  
 suggests that the research places subjects or others at a greater risk of harm (including physical, 
psychological, economic, or social harm) than w as previously known or recognized.  
If an UE occurs the IRB will be notified and the study will be adjusted as needed to protect the 
health and safety of the participants.  Depending on the nature of the UE, the research protocol, 
inclusion/exclusion criter ia, and informed consent will be changed to reflect the possibility of 
this event reoccurring. During this time, no new participants will be recruited and the research 
procedures for currently enrolled participants will be stopped.  Each UE will be recorde d and 
reported throughout the study.      
10.3  REPORTING PROCEDURES  
We will be adopting the following table for reporting procedures:  
What Event is Reported  When is Event Reported  By [CONTACT_84043] -threatening 
unexpected, suspected 
serious adverse reactions  Within 24 hours of initial 
receipt of information  Investigator  Local/internal IRBs  
Non -fatal, non -life 
threatening unexpected, 
suspected serious 
adverse reactions  Within 48 hours  of initial 
receipt of information  Study Coordinator  Local/internal 
IRBs/Institutional 
Officials, DSMB  
Unanticipated adverse 
device effects  Within [ADDRESS_91644]  Investigator  Local/internal IRBs  
Unanticipated pro blem 
that is not an SAE  Within 7 days  of the 
investigator becoming 
aware of the problem  Investigator  Local/internal 
IRBs/Institutional officials  
All Unanticipated Within 30 days  of the IRB OHRP  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 36 Problems  IRB’s receipt of the report 
of the UP from the 
investigator  Investigator  External IRBs  
10.3.[ADDRESS_91645] tACS would interfere with pregnancy. However, 
should a participant become pregnant during the study, their participation will be immediately 
terminated and will be sent to consult with the Co -I and medical monitor.  
10.4  TYPES AND DURATION O F FOLLOW -UP OF PARTICIPANTS A FTER ADVERSE EVENTS  
Medical monit ors and Co -I will follow up with participants within one week of an AE.  
 
 
  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 37 11 STATISTICAL PLAN  
11.1  STATISTICAL ANALYSIS  STRATEGIES  
Our study design is a AB/BA crossover and we will ensure  a washout effect by [CONTACT_43413] 1 -3 weeks 
between stimulation sessions. A continuous outcome approach will be used to analyze the crossover 
trial data where carryover effects will be assumed to be equal.  
Primary outcome: Use kubios software to analyze HRV  over before and after  stimulation. A standard 
spectral analysis will be applied to the pre and post  interval s, incl uding total power, HF, LF, and HP . 
Specifically looking at the HF component since it reflects the parasympathetic modulation of the heart 
rate. Use a repeated measure ANOVA with factor session (1 vs 2) and factor treatment  (active vs sham) 
(R software). We hypothesize a treatment main effect and with no session effect and no interaction.  
Secondary outcome: A Mann -Whitney -Wilcoxon rank -sum test Mann Whitney U test (R software) will be 
performed on the self -report VAS pain scale (nonparametric scale) (from DVPRS) before and after 
stimulation as well as between sessions to analyze any differences in self -report perceived pain. 
Grouped ANOVAs and un paired t -tests may also be used to analyze correlations within other self -report 
measures  
11.2  SAMPLE SIZE DETERMIN ATION  
This clinical trial represents a pi[INVESTIGATOR_799]. A pi[INVESTIGATOR_9962] a clinical trial that is conducted to decide 
whether a new treatment sho uld be tested in a large controlled trial; therefore, we do not calculate 
sample size. This study can be considered a pi[INVESTIGATOR_799], as it is the first time this specific treatment will 
be performed on this clinical population. The results from this study wi ll be used to determine sample 
sizes for future, large -scale clinical trials. In addition, we have to restrict the number of included 
participants to a small sample size due to limited funding resources.  
11.[ADDRESS_91646] that is stored separately in a secured location.  
  
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91647] of 1996 (HIPAA). Those 
regulations require a signed subject authorization informing the subject of the following:  
 What protecte d health information (PHI) will be collected from the participants in this study  
 Who will have access to that information and why  
 Who will use or disclose that information  
 The rights of a research subject to revoke their authorization for use of their PHI.  
In the event that a participant revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability to use all information collected prior to the revocation of participant 
authorization. For participants that have revoked aut horization to collect or use PHI, attempts should be 
made to obtain permission to collect at least vital status (i.e., that the subject is alive) at the end of their 
scheduled study period.  
12.2  CONFIDENTIALITY  
To ensure confidentiality, all data will only  be referenced by a dummy identifier. Source documents (i.e. 
paper forms) will be kept in a locked file cabinet in a locked office. In addition, all data will be stored on 
a password -protected computer using a password -protected data collection tool (REDCa p). The key 
linking dummy identifiers with participant information will be securely located separate from all other 
data collected.  
12.2.[ADDRESS_91648] -protected desktop computer in the Frohlich Lab (Neuroscience Research 
Building 4129).  
12.2.2  SENSITIVE INFORMATIO N 
Sensitive information will be collected in this s tudy, including information about medical 
conditions and drug use. We are using the DASS -21and HAM -D to assess comorbid depression 
and ensure that the participant meets eligibility criteria (low suicide risk).  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 39 12.2.3  OTHER  
Please note that there is no sig nificant risk of deductive disclosure in this study. In addition, 
none of the groupi[INVESTIGATOR_84008].  
12.3  SOURCE DOCUMENTS  
Source data is all information, original records of c linical findings, observations, or other activities in a 
clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in 
source documents. Source data include:  
PARTNERS HUMAN RESEARCH COMMITTEE (IRB).  
 All IRB corre spondences are documented  
 The study staff is IRB approved prior to performing any study procedures  
 Adverse events and deviations are reported to the IRB per current guidelines and stored appropriately  
 All versions of the IRB protocols and informed consent forms are on file  
INFORMED CONSENT . 
 Ensure that participant identification is not recorded on the ICF (i.e., no participant ID)  
 There is documentation that the participant is given a copy of the consent form  
 The participant and study representative signed and dated the consent form for him/herself  
 The participant initialed and dated all appropriate pages on the informed consent form  
 Note to file (Appendix F) made for any informed consent deviations  
 Ensure a valid (current version date) copy of the consent f orm was used  
PROTOCOL DEVIATIONS . 
 Any and all protocol deviations (exceptions and violations) are documented in the participant folder and 
reported to the IRB as required  
OTHER SOURCE DOCUMENTS . 
 Each participant folder will contain a checklist to ensure that all source documents are administered and 
collected properly. The checklist will be dated by [CONTACT_84044]  
 Review participant folders to ensure the accuracy, completeness, and legibility of the data.  
 Any co rrection made to the source documents is dated, initialed, and explained. The original entry should 
not be obscured.  
 The protocol -specific source documents are on file.  
 Source documents are completed in ink.  
 Note to files (Appendix F) are made for missing or incomplete data and to explain any discrepancies or 
additional comments.  
DNA.  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 40  Participant names will not be on any of the samples collected. DNA is sequenced to check for one 
nucleotide. When testing is performed, only de -identified information is share d with an outside party. 
This information will not be shared with anyone outside of the study personnel, including the participant.  
12.4  DATA MANAGEMENT RESP ONSIBILITIES  
The responsibilities designated to each member of the research team are documented on  the 
Delegation of Authority Form. The study coordinator and research assistants will be responsible for the 
informed consent process, review for eligibility, questionnaire administration, data entry, device 
administration, and EKG administration. The stud y coordinator will be responsible for AE/SAE 
documentation and reporting, while the PI [INVESTIGATOR_84009], review of the AE 
documentation forms, and overview of the research staff. Karen McCulloch will be the medical monitor 
for the study.  
REDCap will serve as a secure data management tool for this study. The study coordinator and research 
assistants will have complete access to the REDCap system, while the PI [INVESTIGATOR_7706] -I will have read -only 
ability. This will enable to researchers to e nter the data and the PI [INVESTIGATOR_7706] -I to review.  
12.5  DATA CAPTURE METHODS  (REDCAP)  
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical 
laboratory data will be entered into a data capture system provided by [CONTACT_61604]. The data system 
includes password protection and internal quality checks, such as automatic range checks, to identify 
data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the 
source documents.  
All as sessments completed by [CONTACT_61605], ensuring 
participant security and confidentiality.  
12.[ADDRESS_91649] information such as the date the deviation occurred, details of what the deviation consisted 
of, any corrective and preventative actions that were taken as a result of the deviation, and the date 
that the PI [INVESTIGATOR_84010]. The PI [INVESTIGATOR_84011]. A 
completed copy of the Protocol Deviation Form will be maintained in the regulatory file, as well a s in the 
participant’s source document. Protocol deviations will be sent to the IRB per their guidelines. The site 
PI/study staff will be responsible for knowing and adhering to their IRB requirements.  
12.[ADDRESS_91650] RETENTION  
According to the University of N orth Carolina at Chapel Hill’s Archives and Record Management Services 
schedule for General Records Retention and Disposition Schedule 6.10, records will be kept for 5 years 
after the completion of the study or grant end date, whichever is later.  
  
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91651]  
The investigator will ensure that this study is conducted in full conformity with the principles set forth in 
the Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, 
as drafted by [CONTACT_84045] (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6; 62 Federal 
Regulations [ZIP_CODE] (1997).  
13.[ADDRESS_91652] (IRB)  
The Office of Human Research Ethics is responsible for ethical and regulatory oversight of research at 
UNC -Chapel Hill that involves human participants. The OHRE administers, supports, and guides the work 
of the Institutional Review Boards and all related  activities. Any research involving human participants 
proposed by [CONTACT_61607], staff, or students must be reviewed and approved by [CONTACT_84046], and before related grants may be funded. OHRE and the IRBs are critical components of the 
coor dinated Human Research Protection Program, which serves to protect the rights and welfare of 
human participants. All components of this program must work together to ensure institutional 
compliance with ethical principles and regulatory requirements. The f ollowing is a mission statement for 
the coordinated Human Research Protection Program:  
The University of North Carolina at Chapel Hill is committed to expanding and disseminating knowledge 
for the benefit of the people of North Carolina and the world. An i mportant part of that commitment to 
knowledge is research of the highest quality on all aspects of the health and behavior of people, and 
such research is only possible through the participation of humans as research participants. Human 
participants are pa rtners in research and a precious resource to the university. At UNC -Chapel Hill, 
human participant research is a privilege, but not a right. Consistent with that philosophy, it is the 
mission of the UNC -Chapel Hill Human Research Protection Program to ens ure that:  
a. The rights and welfare of human participants are paramount in the research process;  
b. The highest standards of ethical conduct are employed in all research involving human participants;  
c. Research investigators are properly trained in the ethical and  regulatory aspects of research with human 
participants;  
d. Research investigators deal honestly and fairly with human participants, informing them fully of 
procedures to be followed, and the risks and benefits of participating in research; and  
e. Research using  human participants at UNC -CH conforms to applicable local, state, and federal laws and 
regulations and the policies of the university.  
13.3  INFORMED CONSENT PRO CESS  
Informed consent is a process that is initiated prior to the individual’s agreeing to part icipate in the 
study and continues throughout the individual’s study participation. Extensive discussion of risks and 
possible benefits of tACS will be provided to the participants and their families. Consent forms 
describing, in detail, the study interven tion, device, procedures, and risks are given to the participant 
and written documentation of informed consent is required prior to the administration of any treatment 
BPPS   Version 1.0  
17-0870   3/19/[ADDRESS_91653] the opportunity to 
discuss the study with their surrogates or think about it prior to agreeing to partic ipate.  Participants 
may withdraw consent at any time throughout the course of the trial.  A copy of the informed consent 
document will be given to the participants for their records.  The rights and welfare of the participants 
will be protected by [CONTACT_84047].  
13.4  EXCLUSION OF WOMEN, MINORITIES, AND CHIL DREN (SPECIAL POPULA TIONS)  
Non -English speaking individuals are excluded because t he ability to accurately and complete 
communicate study information, answer questions about the study, and obtain consent is necessary. 
Female participants will be asked if there is any reason to believe they might be pregnant. Pregnant 
participants will b e excluded despi[INVESTIGATOR_84012], since no safety data for pregnancy is known to exist for transcranial current stimulation studies. 
All women of child -bearing potential will be asked to take a pregn ancy test during the initial session in 
order to determine eligibility for the study.  
13.[ADDRESS_91654] 
participant’s willingness to continue will be communicated within 2 days of the PI [INVESTIGATOR_84013].  
  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 43 14 PUBLICATION POLICY  
This study will be registered on clinicaltrials.gov once IRB approved. There are no restrictions on 
publications since this is an investigator -initiated study funded by a grant agency that has no influence 
on the publications result ing from this study. The aim is to publish the results of this study in a peer -
reviewed, psychiatry or physical therapy journal.  
  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 44 15 LITERATURE REFERENCE S 
Andersson, Eleonor I., Christine C. Lin, and Rob JEM Smeets. "Performance tests in people with chro nic 
low back pain: responsiveness and minimal clinically important change." Spi[INVESTIGATOR_050] 35, no. 26 (2010): E1559 -
E1563  
Antal, A., Chaieb, L., Moliadze, V., Monte -Silva, K., Poreisz, C., Thirugnanasambandam, N., & ... Paulus, 
W. Brain -derived neurotrophic factor (BDNF) gene polymorphisms shape cortical plasticity in humans. 
Brain Stimulation, (2010a): 3(4), 230 -237. doi:10.1016/j.brs.2009.12.003  
Antal, Andrea, Daniella Terney, Stefanie Kühnl, and Walter Paulus. "Anodal transcranial direct current 
stimulation of th e motor cortex ameliorates chronic pain and reduces short intracortical inhibition." 
Journal of pain and symptom management 39, no. 5 (2010): 890 -903.  
Balanescu S, Corlan AD, Dorobantu M, et al. Prognostic value of heart rate variability after acute 
myocar dial infarction. Med Sci Monit. 2004;10:CR307 –CR315  
Baliki, Marwan N., and A. Vania Apkarian. "Nociception, pain, negative moods, and behavior selection." 
Neuron 87, no. 3 (2015): 474 -491.  
Berlim, M.T., Van den Eynde, F., and Daskalakis, Z.J. (2013).  Clinical utility of transcranial direct current 
stimulation (tDCS) for treating major depression: a systematic review and meta -analysis of randomized, 
double -blind and sham -controlled trials. Journal of psychiatric research 47, [ADDRESS_91655], Rosemary C. Polomano, Mary McDuffie, Nancy Kwon, and 
Rollin M. Gallagher. "Preliminary validation of the Defense and Veterans Pain Rating Scale (DVPRS) in a 
military population." Pain Medicine 14, no. 1 (2013): [ADDRESS_91656] A. Deyo. "The effectiveness and risks of long -term opi[INVESTIGATOR_84014]: a systematic review for a National Institutes of Health Pathways to Prevention Workshop." 
Annals of internal medicine 162, no. 4 (2015): 276 -286.  
Cooper, N. R., Croft, R. J., Dominey, S. J., Burgess, A. P., & Gruzelier, J. H. (2003). Paradox lost? Exploring 
the role of alpha oscillations during extern ally vs. internally directed attention and the implications for 
idling and inhibition hypotheses. International Journal of Psychophysiology, 47(1), 65 -74. 
doi:10.1016/s0167 -8760(02)[ADDRESS_91657]., 15 (2015), pp. 272 –278 
 
Freburger, J. K., Holmes, G. M., Agans, R. P., Jackman, A. M., Darter, J. D., Wallace, A. S., … Carey, T. S. 
The Rising Prevalence of Chronic Low Back Pain. Archives of Interna l Medicine. (2009):169(3), 251 –258. 
http://doi.org/10.1001/archinternmed.2008.543  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 45 Freburger, Janet K., Timothy S. Carey, and George M. Holmes. "Physical therapy for chronic low back 
pain in North Carolina: overuse, underuse, or misuse?." Physical therapy 9 1, no. 4 (2011): 484.  
Fregni, Boggio PS, Lima MC, et al. A sham -controlled, phase II trial of transcranial direct current 
stimulation for the treatment of central pain in traumatic spi[INVESTIGATOR_84015], 122 (2006), pp. 197 –
209.  
Fritz JM, Irrgang JJ. A c omparison of a modified Oswestry Low Back Pain Disability Questionnaire and the 
Quebec Back Pain Disability Scale. Phys Ther. 2001; 81(2):776 -788.  
Fröhlich F and McCormick DA. Endogenous Electric Fields May Guide Neocortical Network Activity. 
Neuron. 2010 July; 67(1):[ADDRESS_91658] current stimulation (tDCS) as a treatment for auditory hallucinations in 
schizophrenia. Europea n Psychiatry. (March 2016).  
Fröhlich F. Tuning out the Blues – Thalamo -Cortical Rhythms as a Successful Target for Treating 
Depression. Brain Stimulation. (2015) Nov -Dec; 8(6):1007 -9. doi: 10.1016/j.brs.2015.07.040.  
Gaeta, G., Susac, A., Supek, S., Babilon i, F., & Vecchiato, G. (2015). Analysis of EEG variables to measure 
the affective dimensions of arousal and valence related to the vision of emotional pi[INVESTIGATOR_499]. 2015 37th 
Annual International Conference of the IEEE Engineering in Medicine and Biology Socie ty (EMBC). 
doi:10.1109/embc.2015.[ADDRESS_91659]. "The economic costs of pain in the [LOCATION_002]." The Journal of 
Pain 13, no. 8 (2012): 715 -724.  
Hamilton, M. (1960). A RATING SCALE FOR DEPRESSION. Journal of Neurology, Ne urosurgery, and 
Psychiatry, 23(1), 56 –62. 
Hariri, A. R., Goldberg, T. E., Mattay, V. S., Kolachana, B. S., Callicott, J. H., Egan, M. F., & Weinberger, D. 
R. (2003). Brain -Derived Neurotrophic Factor val⁶⁶ met Polymorphism Affects Human Memory -Related 
Hipp ocampal Activity and Predicts Memory Performance. The Journal Of Neuroscience, 23(17), 6690 -
6694.  
 Jeffries L.J., Milanese S.F., and Grimmer -Somers K.A.: Epi[INVESTIGATOR_84016]: a 
systematic overview of the research literature. Spi[INVESTIGATOR_050] 2007; 32: pp. [ADDRESS_91660], Jeffrey J. Borckardt, and Alok Madan. "A single -blind, randomized control trial of adjunctive 
transcranial direct current stimulati on (tDCS) for chronic pain among patients receiving specialized, 
inpatient multimodal pain management." Contemporary Clinical Trials (2016).  
Kang, Jiunn -Horng, et al. "Disability in patients with chronic neck pain: heart rate variability analysis and 
clust er analysis." The Clinical journal of pain 28.9 (2012): 797 -803.  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 46 Kasten, F. H., Dowsett, J., & Herrmann, C. S. (2016). Sustained Aftereffect of α -tACS Lasts Up to 70 min 
after Stimulation. Frontiers in Human Neuroscience Front. Hum. Neurosci., 10. 
doi:10.3 389/fnhum.2016.[ZIP_CODE]  
Kleim, J. A., Chan, S., Pringle, E., Schallert, K., Procaccio, V., Jimenez, R., & Cramer, S. C. (2006). BDNF 
val66met polymorphism is associated with modified experience -dependent plasticity in human motor 
cortex. Nature Neuroscience, 9(6), 735 -737. doi:10.1038/nn1699  
Lim, M.et al. (2016) Increased low - and high -frequency oscillatory activity in the prefrontal cortex of 
fibromyalgia patients. Front. Hum. Neurosci. 10, 111.  
Lovibond, S.H.; Lovibond, P.F. (1995). Manual for the Depression  Anxiety Stress Scales (2nd ed.). Sydney: 
Psychology Foundation (Available from The Psychology Foundation, Room [ADDRESS_91661] Mueller, and Arne 
May. "Effectiveness of transcranial direct current stimulation preceding cognitive behavioural 
management for chronic low back pain: sham controlled double blinded randomised controlled trial." 
bmj 350 (2015): h1640.  
Lusten berger, C., Boyle, M. R., Foulser, A. A., Mellin, J. M., & Fröhlich, F. (2015). Functional role of frontal 
alpha oscillations in creativity. Cortex, 67, 74 -82. doi:10.1016/j.cortex.2015.03.012  
Martin BI, Deyo RA, Mirza SK, Turner JA, Comstock BA, Hollingwo rth W, et al. Expenditures and health 
status among adults with back and neck problems. JAMA. 2008;299(6):656 –664.  
Montenegro, Rafael Ayres, et al. "Transcranial direct current stimulation influences the cardiac 
autonomic nervous control." Neuroscience lett ers 497.1 (2011): 32 -36. 
Naro, Antonino, Demetrio Milardi, Margherita Russo, Carmen Terranova, Vincenzo Rizzo, Alberto 
Cacciola, Silvia Marino, Rocco S. Calabro, and Angelo Quartarone. "Non -invasive brain stimulation, a tool 
to revert maladaptive plasticity in neuropathic pain." Frontiers in human neuroscience 10 (2016).  
Nicholas, M. K. (2007). The pain self -efficacy questionnaire: Taking pain into account. European Journal 
of Pain, 11(2), 153 -163.  
Pengel L.H., Herbert R.D., Maher C.G., and Refshau ge K.M.: Acute low back pain: systematic review of its 
prognosis. BMJ 2003; 327: pp. 323  
Perret, Caroline, Serge Poiraudeau, Jacques Fermanian, Marie Martine Lefèvre Colau, Marie Anne 
Mayoux Benhamou, and Michel Revel. "Validity, reliability, and responsiv eness of the fingertip -to-floor 
test." Archives of physical medicine and rehabilitation 82, no. 11 (2001): 1566 -1570.  
Pezawas L.,Verchinski B.A., Mattay V.S., Callicott J.H., Kolachana B.S., Straub R.E., Egan M.F., Meyer -
Lindenberg A, Weinberger D.R. (2004 ). “The Brain -Derived Neurotrophic Factor val66met Polymorphism 
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 47 and Variation in Human Cortical Morphology.” The Journal of Neuroscience 24 (45): [ZIP_CODE] –102. 
doi:10.1523/JNEUROSCI.2680 -04.2004.  
Ploner, Markus, Christian Sorg, and Joachim Gross. "Brain Rhyth ms of Pain." Trends in Cognitive Sciences 
(2016).  
Simmonds, M. J., Olson, S. L., et al. (1998). "Psychometric characteristics and clinical usefulness of 
physical performance tests in patients with low back pain." Spi[INVESTIGATOR_050] (Phila Pa 1976) 23(22): 2412 -2421  
Södervall J, Karppi[INVESTIGATOR_23056] J, Puolitaival J, et al. Heart rate variability in sciatica patients referred to spi[INVESTIGATOR_84017]: a case control study. BMC Musculoskeletal Disorders. 2013;14:149. doi:10.1186/1471 -2474 -14-
149.  
Staud R. Heart rate variability as a biomark er of fibromyalgia syndrome. Fut Rheumatol. 2008;3:475 –483 
Sullivan M J L, Bishop S, Pi[INVESTIGATOR_8331] J. The Pain Catastrophizing Scale: Development and validation. Psychol 
Assess (1995) 7: 524 -532.  
Walker B.F., Muller R., and Grant W.D.: Low back pain in Australian adults: prevalence and associated 
disability. J Manipulative Physiol Ther (2004); 27: pp. 238 -244 
Weinreich, A., Stephani, T., & Schubert, T. (2016). Emotion effects within frontal alpha oscillation in a 
pi[INVESTIGATOR_84018]. International Journal of P sychophysiology. doi:10.1016/j.ijpsycho.2016.07.517  
ZAEHLE, T., RACH, S. , & HERRMANN, C. S. (2010). TRANSCRANIAL  ALTERNATING CURRENT 
STIMULATION ENHANCES  INDIVIDUAL ALPHA ACT IVITY IN HUMAN EEG. PLOS ONE, 5(11), 
E13766. 
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 48 APPENDIX A: SCHEDULE  OF EVENTS  
A detailed schematic describing all visits and assessments.  
Procedures  Phone Screening  First Stimulation 
(Sham or 10 Hz)  2 Days Later  Second 
Stimulation 
(Sham or 10 Hz)  2 Days Later  
Provide Verbal Consent  x     
Signed Consent Form   x    
Signed HIPAA Authorization   x    
Assessment of Eligibility Criteria  x x    
Review of Medical History  x x    
Review of Concomitant Medications  x x    
Baseline Assessments (list 
assessments)   x    
Clinical Assessments   x  x  
Pressure Pain Threshold Test   x  x  
Urine Pregnancy Test   x    
Randomization   x    
Stimulation   x  x  
Stimulation Questionnaire, Perceived 
Improvement Questionnaire, HAM -D   x  x  
Email Questionnaires (Follow -up)   x  x 
      
 
 
 
 
 
 
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 49 APPENDIX B: AE REPOR T FORM  
 
Adverse Effects Report:  
Reasons for Report (adverse event, time, date and place of occurrence if available) :  
1. What do we already know about the therapy?  
a.  
2. What is the temporal relationship of the AE to the study therapy?  
a.  
3. Does the AE improve or disappear when the therapy is stoppe d? 
a.  
4. Is the AE a worsening of baseline symptom(s)?  
a.  
5. Is the AE a result of an underlying concurrent medical condition(s) or concurrent 
medication(s)?  
a.   
6. Additional Information provided by [CONTACT_84048]  
a.  
Research team member signature ________________________ ______________ 
Date____________  
Co-Investigator:  
______________________________________________________________________________
______________________________________________________________________________
__________________________________________________ ____________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________  
 
Steps to be taken (if applicable)  
______ ________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
____________________________ __________________________________________________
______________________________________  
Co-I signature 
_______________________________________________________Date___________  
 
PI [CONTACT_72411]:  
__________________________________________________________________ ____________
______________________________________________________________________________
______________________________________________________________________________
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 50 ______________________________________________________________________________
__________ ____________________________________________________________________
______________________________  
 
Steps to be taken (if applicable)  
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________ ________________________________________________________
______________________________________  
 
PI [INVESTIGATOR_59844] 
_______________________________________________________Date___________  
  
  
CONFIDENTIAL  
 51 APPENDIX C: IRB AMEN DMENT TRACKING LOG  
 
Change Initiated By:  
[CONTACT_61613]: Type and Brief Summary  Date 
Submitted 
to IRB Date of 
IRB 
Response  Requires 
Stipulations? 
(Y/N)  Requires 
Updated 
Consent 
Form? 
(Y/N)  Stipulation 
Submission 
Date  IRB 
Approval 
Date  Initials  Reference 
ID 
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 52 APPENDIX D: AE REPOR T FORM  
 
Participant 
ID  if AE meets 
definition of 
serious*  Grade/Intensity  
1. Asymptomatic  
2. Mild  
3. Moderate  
4. Severe  
 Date of 
Incident  Relationship to 
study device  
1. Related  
2. Possibly  
3. Not Likely  
4. Not Related  Was Action 
Taken?  
 
 
 
 Action(s) Taken:  Outcome:  
1. Recovered  
2. Not Recovered  
3. Recovered 
w/Sequel  
4. Fatal  
5. Unknown  PI [CONTACT_74938] / Date  
     Yes  /  No     
     Yes  /  No     
     Yes  /  No     
     Yes  /  No     
     Yes  /  No     
     Yes  /  No     
     Yes  /  No     
     Yes  /  No     
     Yes  /  No     
     Yes  /  No     
 
  
  
CONFIDENTIAL  
 53  
APPENDIX E: INFORMED  CONSENT QUIZ  
Name [CONTACT_61617]:  
You have been asked to be in a research study. This sheet will help you think of questions to ask 
but you may have other questions.  This is not a test.  We want to be sure you understand what 
it means to be in this research study.  You should understand the research before you decide 
whether or not to participate.  
1. What is the purpose of the research?  
2. What are the possible benefits of the research?  
3. What are the possible risks of the research?  
4. Will everyone receive the same treatment?  
5. How is this research different than the care or treatm ent I would get if I wasn’t in the 
research study?  
6. Does the research cost me anything extra?  
7. Can you stop being in the research once you’ve started?  
8. Who will view your medical records?  
9. Who do you call if I have questions about being a research subject?  
10. Any questions?   
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 54 APPENDIX F: NOTE TO FILE  
 
IRB#: 15 -2125                      PI: [INVESTIGATOR_84019]: [Insert Short Name]  
Researcher: ________________             Date of Occurrence: ____________  
Participant ID: _________________  
 
Reason for Note: 
_____________________________________________________________________________________
_____________________________________________________________________________________  
 
Note: 
_________________________________________________________________________________ ____
_____________________________________________________________________________________
_____________________________________________________________________________________
__________________________________________________________________________________ ___
_____________________________________________________________________________________
_____________________________________________________________________________________
___________________________________________________________________________________ __
_____________________________________________________________________________________
_____________________________________________________________________________________
____________________________________________________________________________________ _
_____________________________________________________________________________________  
 
Corrective action (if applicable): 
_____________________________________________________________________________________
________________________________________________ _____________________________________
_____________________________________________________________________________________  
 
 
Signature: ______________________________       Date: _______________  
 
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 55 APPENDIX G: TELEPHON E SCRIPT  
Hello, my name [CONTACT_832] __________ and I am a study coordinator from the University of North Carolina at 
Chapel Hill conducting a research study about individuals with chronic low back pain. Based on your 
medical history, you may be eligible to participate in ou r study.  
 
 If participant asks “ How did you get my name [CONTACT_3669] [CONTACT_3031]?”   
o Answer :  We received IRB approval to access medical records of patients in the UNC Health Care 
System who meet our research study criteria.  Based on your medical history, you appear eligible 
to participate in this study.  If you are not interested in participating in this study, we will destroy 
all information that we have already collected about you.  
 If participate states, “but I am not a UNC Health Care patient, I go to R ex Hospi[INVESTIGATOR_307].”  
o Answer : UNC Health Care System now in cludes several affiliate hospi[INVESTIGATOR_4813], include Rex.  
 
Do you have time now to hear about the study, answer a few screening questions, and schedule your 
first visit?  
(If ‘No’, ask for a good time to call back)   
(If ‘Yes’, proceed)  
 
Great!  This study is looking at abnormal rhythms of brain activity in patients with chronic low back pain 
and how they respond to very weak applied electric currents.  Findings from this study will help the 
development of treatments for the symptoms of chronic pain.  In this study, a very weak electric current 
will be applied to your scalp.  Some people report a mild tingling because of this stimulation, but no 
other side effects have been found.  It is not a shock and s hould cause no pain.  
 
Participation in this study includes two sessions, consisting 2 stimulation sessions, separated by 1 -3 
weeks. You will be compensated for your time spent participating in the study. The maximum 
compensation for this study is $55 for c ompleting all of the sessions. Are you still interested in 
participating?  
 
(If ‘No’, thank them for their time; if ‘Yes’, proceed)  
 
Great! In order to make sure you’re eligible for the study, I need to ask you a few questions. Please 
answer yes or no. You do not need to provide any further details.  
(If the answer given is not the same as the answer shown, thank the individual for his or her interest and 
say, unfortunately, they do not qualify for the current study)  
 
 Are you 18 years old or older?  (Yes)  
 Have you ever, or are you currently being treated for a neurological condition (e.g., epi[INVESTIGATOR_002], migraines)? (No)  
 Are you currently tak ing medication for the treatment of chronic pain or any other psychiatric illness?  
o Have you ever taken medication for chronic pain?  
o Have you taken ever taken opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_84020]?  
 If yes, has it been at least 6 months sinc e then?  
 Have you ever had brain surgery? (No)  
 Do you have any brain devices or implants, including a cochlear implant or aneurysm clip? (No)  
 Have you ever been diagnosed with a traumatic brain injury?  
o If yes, how severe?  
 (For females only) Is there a chanc e you may be pregnant? (No)  
 
Diagnostic  
BPPS   Version 1.0  
17-0870   3/19/17  
CONFIDENTIAL  
 56  Have you been diagnosed with chronic lower back pain by a professional (i.e., a physical therapi[INVESTIGATOR_84021])?  
 Have you been diagnosed with any other co -morbid pain conditions such as fibromyalgia, nerve damage, or 
multiple sclerosis?  
 Do you have chronic pain anywhere besides your back)?  
 Does your pain radiate to other parts of your body (i.e. down your leg)? (radicular pain)  
Follow -up Questions  
 Have you ever been hospi[INVESTIGATOR_057]?  
o If yes, was it in any way related to your chronic pain or another psychiatric condition?  
o If yes, when did this occur?  
 
Phone Screening:  
 Pass  
 Fail 
Reason for failing: ________________________________________________________  
   __________________________________________________ _____________________  
   _______________________________________________________________________  
Initials _______  
 
You are eligible for participation in the first session of the study. At the first session we will determine 
your eligibility for the remainder of the sessions and complete some baseline assessments.  I’d like to 
schedule your first session now. It will last approximately 2 -4 hours. All testing will be conducted UNC 
Hospi[INVESTIGATOR_307].  
 
Scheduled Initial Session (Enter into Clinical Trials Calend ar) 
  Date: _______________  
  Time: _______________  
 
I will send you an email confirming this time, and providing directions on how to find the specific 
location of your session. We will also send you an email to confirm your appointment [ADDRESS_91662] any questions 
before then, please don’t hesitate to contact [CONTACT_84049] [EMAIL_1668] .  
Thank you for your tim e. 
 
 